Subscribe
Search
Close this search box.
Subscribe
Search
Close this search box.

Oncology

Biomedical/pharma, Oncology

V-Bio Ventures leads €20 million Series A financing of Precision oncology company Flindr Therapeutics to advance first-in-class small molecule inhibitors

Using patient data to enable personalized healthcare, ATHENA shows us how!

Personalized healthcare is characterized by tailoring treatments to each individual patient’s needs. Despite evident benefits, implementing such a system is not straightforward. The ATHENA project consortium has successfully devised a set of building blocks to address the challenges associated. Both technological and governance tools were developed that can now be used on a larger scale to catalyze the transition towards personalized medicine and care.

Fund+ Portfolio Company Tubulis Closes Upsized EUR 128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline

  • Financing round co-led by EQT Life Sciences and Nextech Invest1, with participation from current and new leading global biotechnology investors
  • Proceeds will support clinical evaluation of lead solid tumor ADC candidates, TUB-030 and TUB-040, further technology development and expansion into the US

QbD Chair for Precision Oncology Research in Glioblastoma extended for three years

The QbD Chair supports the research of Professor Frederik De Smet on glioblastoma, an aggressive form of brain cancer. Behind the establishment of the Chair lies a personal story.

Pioneering Belgian project ATHENA paves the way for Real-World Data reuse in research and personalized care

ATHENA, a VLAIO-funded multi-stakeholder project, clears the path for increased reuse of Real-World Data in scientific research and healthcare, by introducing innovative solutions and responding to current technical and governance challenges. The project has made significant strides in the field of oncology by developing groundbreaking privacy-preserving machine learning techniques for predictive analytics. The project findings will be presented and discussed at the ATHENA symposium on November 23rd, 2023.

The rise of women’s health

It’s been a Barbie world this summer with crowds of pink-clad moviegoers flooding the cinemas. Simultaneously, we’ve been witnessing a rush of ‘pink’ fundraising for women’s health start-ups. From pre-clinical to clinical: more companies are entering the field and developing solutions for women’s unique needs. But is their focus broad and innovative enough? And are pharma companies paying attention?

miDiagnostics announces collaboration with Galapagos to develop closed-flow, ultra-rapid CAR-T sterility test for its point-of-care CAR-T manufacturing platform

miDiagnostics NV, a global technology leader in point-of-care diagnostics, today announced a collaboration agreement with Galapagos to develop a closed-flow, ultra-rapid PCR sterility test for CAR-T batch release in a decentralized manufacturing setting, in compliance with regulatory requirements, including those in the U.S., Europe and Japan.

Byteflies: virtual care solutions for all

Byteflies is on a mission to make virtual care available to all. The Belgian company has developed a platform for remote patient monitoring solutions, to save precious time for healthcare providers, reduce hospitalization costs, and boost the quality of life for patients. The aim is to aid the transition from fragmented to connected healthcare, enabling a continuum of care through virtual solutions.

Dosing flash radiation for the future of cancer treatment

Cancer vaccines: not only treating tumors, but preventing them too

New personalized cancer vaccine in the making thanks to unique Belgian collaboration

V-Bio Ventures leads Sibylla Biotech’s EUR 23 million Series A to advance a novel therapeutic approach for undruggable diseases

Augustine Therapeutics: time to reverse nerve damage in patients undergoing chemotherapy or with Charcot-Marie-Tooth disease

Augustine Therapeutics appoints Gerhard Koenig as Chairman of the Board, forms Clinical Advisory Board, and broadens therapeutic indications

IBA and SCK CEN partnership to produce rare radioisotope for cancer treatments